| | |
| Alkermes Contacts: | |
| For Investors: | Sandy Coombs +1 781 609 6377 |
| | Eva Stroynowski +1 781 609 6823 |
| For Media: | Jennifer Snyder +1 781 609 6166 |
Alkermes Plc Reports Second Quarter 2018 Financial Results
— Second Quarter Revenues Increase to $304.6 Million, Driven by License Revenues and 24% Year-Over-Year Growth of Proprietary Product Net Sales —
— Company Reports GAAP Net Loss per Share of $0.21 and Diluted Non-GAAP Earnings per Share of $0.29 —
— Company Reiterates Financial Expectations for 2018 —
DUBLIN, Ireland, July 26, 2018 — Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2018.
“Our strong second quarter results were driven by the solid growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, as well as the receipt of a $50 million payment related to our collaboration with Biogen for BIIB098,” commented James Frates, Chief Financial Officer of Alkermes. “The business is performing as planned and today we are reiterating our financial expectations for 2018. As we head into a catalyst-rich second half of the year, we are well-positioned financially to drive value, grow our portfolio of commercial products and advance our late-stage pipeline.”
Quarter Ended June 30, 2018 Financial Highlights
• Total revenues for the quarter were $304.6 million. This compared to $218.8 million for the same period in the prior year, representing an increase of 39%. Proprietary product net sales for VIVITROL® and ARISTADA® were $109.8 million for the quarter, reflecting a 24% increase compared to the same period in the prior year.
• Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $32.6 million for the quarter, or a basic and diluted GAAP net loss per share of $0.21. This compared to GAAP net loss of $43.0 million, or a basic and diluted GAAP net loss per share of $0.28, for the same period in the prior year.
• Non-GAAP net income was $45.6 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.29. This compared to non-GAAP net income of $1.2 million, or non-GAAP basic and diluted earnings per share of $0.01, for the same period in the prior year.
“VIVITROL and ARISTADA continue to demonstrate solid growth and perform in-line with our expectations. Our proprietary commercial portfolio is a key growth driver for Alkermes, and we are confident about the prospects ahead for these important products,” stated Jim Robinson, President and Chief Operating Officer of Alkermes. “In particular, the launch of ARISTADA INITIO™ is an important opportunity to support continuity of care and address a critical unmet need for patients, as ARISTADA is now the first and only long-acting atypical antipsychotic that can be fully dosed on day one for up to two months. ARISTADA INITIO represents a key addition to the treatment paradigm for schizophrenia and provides a platform to further expand utilization of ARISTADA.”
Quarter Ended June 30, 2018 Financial Results
Revenues
• Net sales of VIVITROL were $76.2 million, compared to $66.1 million for the same period in the prior year, representing an increase of approximately 15%.
• Net sales of ARISTADA were $33.6 million, compared to $22.7 million for the same period in the prior year, representing an increase of approximately 48%.
• Manufacturing and royalty revenues from RISPERDAL CONSTA®, INVEGA SUSTENNA®/XEPLION® and INVEGA TRINZA®/TREVICTA® were $85.2 million, compared to $82.2 million for the same period in the prior year.
• Manufacturing and royalty revenues from AMPYRA®/FAMPYRA®1 were $19.7 million, compared to $25.3 million for the same period in the prior year.
• License revenues from the collaboration with Biogen for BIIB098 (formerly ALKS 8700) were $48.3 million.
• Research and development revenues were $18.3 million, of which $17.2 million related to the collaboration with Biogen for BIIB098.
Costs and Expenses
• Operating expenses were $304.7 million, compared to $263.4 million for the same period in the prior year, primarily reflecting increased investment in the commercialization of VIVITROL and ARISTADA.
• Other expense during the quarter included a $19.6 million charge due to a decrease in the fair value of contingent consideration related to Recro Pharma, Inc.’s receipt of a complete response letter from the United States (U.S.) Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for IV Meloxicam.
“With a growing proprietary commercial portfolio and partnered royalty and manufacturing business approaching $1 billion in revenue in 2018, Alkermes is in a strong position to create significant long-term value. As we head into the second half of 2018, we are on the threshold of important value inflections across our development portfolio,” said Richard Pops, Chief Executive Officer of Alkermes. “For ALKS 5461 for major depressive disorder, the regulatory review is underway and we are preparing for an Advisory Committee meeting in the fourth quarter. For ALKS 3831 for schizophrenia, enrollment of the ENLIGHTEN-2 pivotal study is complete and we expect topline data in the fourth quarter of 2018. In addition, we are on track to submit the NDA for BIIB098 toward year-end, and we look forward to presenting initial data from the ALKS 4230 phase 1 study and expanding into combination therapy later this year.”
Recent Events
• ARISTADA INITIO: Following recent FDA approval, ARISTADA INITIO is now commercially available. The ARISTADA INITIO regimen2 provides physicians with an opportunity to initiate patients onto any dose of ARISTADA on day one.
• ALKS 5461: Data on the long-term safety, tolerability and durability of antidepressant effect of ALKS 5461 were presented at the American Psychiatric Association (APA) and American Society of Clinical Psychopharmacology (ASCP) annual meetings.
• ALKS 3831: The company presented data from the ALKS 3831 preclinical program and phase 1 translational medicine study evaluating the metabolic profile of ALKS 3831 compared to olanzapine.
• BIIB098: Alkermes received a $50 million payment from Biogen in June 2018. This payment follows Biogen's review of preliminary gastrointestinal tolerability data from the ongoing clinical development program for BIIB098.
Financial Expectations for 2018
Alkermes reiterates its financial expectations for 2018 set forth in its press release dated April 26, 2018.
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:30 a.m. ET (1:30 p.m. BST) on Thursday, July 26, 2018, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes’ website at www.alkermes.com. The conference call
may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. In addition, a replay of the conference call will be available from 11:00 a.m. ET (4:00 p.m. BST) on Thursday, July 26, 2018, through 5:00 p.m. ET (10:00 p.m. BST) on Thursday, Aug. 2, 2018, and may be accessed by visiting Alkermes’ website or by dialing +1 888 843 7419 for U.S. callers and +1 630 652 3042 for international callers. The replay access code is 6037988.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with generally accepted accounting principles in the U.S. (GAAP), including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
Non-GAAP net income (loss) adjusts for one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items.
The company’s management and board of directors utilize these non-GAAP financial measures to evaluate the company’s performance. The company provides these non-GAAP measures of the company’s performance to investors because management believes that these non-GAAP financial measures, when viewed with the company’s results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of our liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: future financial and operating performance, business plans or prospects; the likelihood of continued revenue growth from the company’s commercial products, including the growth of VIVITROL and ARISTADA; the potential therapeutic and commercial value of the company’s marketed and development products, and payer coverage of, and patient access to, such products; expectations concerning the timing and results of clinical development and regulatory activities, including the timing of the phase 3 clinical trial (ENLIGHTEN-2) data readout for ALKS 3831, the timing of the submission of the NDA for BIIB098, the timing of initial data from the ALKS 4230 phase 1 study and the expansion of the study into combination therapy, and the outcome and timing of the FDA’s review of the NDA for ALKS 5461; and expectations concerning the timing and results of commercial activities, including the launch of ARISTADA INITIO. The company cautions that forward-looking statements are inherently uncertain. Although the company believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, the forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those
expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so-called “Paragraph IV” litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real-world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company’s products or an increase in the company’s financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company’s products; the company’s products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading “Risk Factors” in the company’s most recent Annual Report on Form 10-K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (“SEC”), which are available on the SEC’s website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.
VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA® is a registered trademark and ARISTADA INITIOTM is a trademark of Alkermes Pharma Ireland Limited; RISPERDAL CONSTA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson; AMPYRA® and FAMPYRA® are registered trademarks of Acorda Therapeutics, Inc.
1AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is developed and marketed in the U.S. by Acorda Therapeutics, Inc. and outside the U.S. by Biogen Idec, under a licensing agreement with Acorda Therapeutics, as FAMPYRA® (prolonged-release fampridine tablets).
2ARISTADA INITIO was approved by the FDA for the initiation of ARISTADA, a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. The ARISTADA INITIO regimen consists of ARISTADA INITIO plus a single 30 mg dose of oral aripiprazole.
(tables follow)
| | | | |
Alkermes plc and Subsidiaries |
Selected Financial Information (Unaudited) |
| | | | |
| | Three Months Ended | | Three Months Ended |
Condensed Consolidated Statements of Operations - GAAP | | June 30, | | June 30, |
(In thousands, except per share data) | | 2018 | | 2017 |
Revenues: | | | | |
Manufacturing and royalty revenues | $ | 128,241 | $ | 129,252 |
Product sales, net | | 109,807 | | 88,756 |
License revenue | | 48,250 | | — |
Research and development revenue | | 18,344 | | 833 |
Total Revenues | | 304,642 | | 218,841 |
Expenses: | | | | |
Cost of goods manufactured and sold | | 43,417 | | 39,775 |
Research and development | | 106,823 | | 99,153 |
Selling, general and administrative | | 138,257 | | 108,950 |
Amortization of acquired intangible assets | | 16,247 | | 15,472 |
Total Expenses | | 304,744 | | 263,350 |
Operating Loss | | (102) | | (44,509) |
Other Expense, net: | | | | |
Interest income | | 1,900 | | 1,171 |
Interest expense | | (3,126) | | (2,923) |
Change in the fair value of contingent consideration | | (19,600) | | 700 |
Other expense, net | | (3,517) | | (119) |
Total Other Expense, net | | (24,343) | | (1,171) |
Loss Before Income Taxes | | (24,445) | | (45,680) |
Income Tax Benefit | | 8,204 | | (2,681) |
Net Loss — GAAP | $ | (32,649) | $ | (42,999) |
| | | | |
Net (Loss) Earnings Per Share: | | | | |
GAAP net loss per share — basic and diluted | $ | (0.21) | $ | (0.28) |
Non-GAAP earnings per share — basic and diluted | $ | 0.29 | $ | 0.01 |
| | | | |
Weighted Average Number of Ordinary Shares Outstanding: | | | | |
Basic and diluted — GAAP | | 155,176 | | 153,392 |
Basic — Non-GAAP | | 155,176 | | 153,392 |
Diluted — Non-GAAP | | 159,761 | | 160,307 |
| | | | |
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows: | | | | |
Net Loss — GAAP | $ | (32,649) | $ | (42,999) |
Adjustments: | | | | |
Share-based compensation expense | | 30,933 | | 22,680 |
Amortization expense | | 16,247 | | 15,472 |
Depreciation expense | | 9,521 | | 9,034 |
Change in the fair value of warrants and equity method investments | | 1,269 | | 1,611 |
Non-cash net interest expense | | 170 | | 193 |
Change in the fair value of contingent consideration | | 19,600 | | (700) |
Income tax effect related to reconciling items | | 512 | | (4,102) |
Non-GAAP Net Income | $ | 45,603 | $ | 1,189 |
| | | | |
Alkermes plc and Subsidiaries |
Selected Financial Information (Unaudited) |
| | | | |
| | Six Months Ended | | Six Months Ended |
Condensed Consolidated Statements of Operations - GAAP | | June 30, | | June 30, |
(In thousands, except per share data) | | 2018 | | 2017 |
Revenues: | | | | |
Manufacturing and royalty revenues | $ | 242,842 | $ | 243,931 |
Product sales, net | | 201,649 | | 165,212 |
License revenues | | 48,250 | | — |
Research and development revenues | | 37,051 | | 1,476 |
Total Revenues | | 529,792 | | 410,619 |
Expenses: | | | | |
Cost of goods manufactured and sold | | 87,893 | | 80,187 |
Research and development | | 215,169 | | 203,988 |
Selling, general and administrative | | 256,404 | | 211,049 |
Amortization of acquired intangible assets | | 32,316 | | 30,774 |
Total Expenses | | 591,782 | | 525,998 |
Operating Loss | | (61,990) | | (115,379) |
Other Expense, net: | | | | |
Interest income | | 3,385 | | 2,114 |
Interest expense | | (8,613) | | (5,687) |
Change in the fair value of contingent consideration | | (21,500) | | 2,300 |
Other expense, net | | (2,725) | | (1,618) |
Total Other Income (Expense), net | | (29,453) | | (2,891) |
Loss Before Income Taxes | | (91,443) | | (118,270) |
Income Tax Provision (Benefit) | | 3,711 | | (6,390) |
Net Loss — GAAP | $ | (95,154) | $ | (111,880) |
| | | | |
Net (Loss) Earnings Per Share: | | | | |
GAAP net loss per share — basic and diluted | $ | (0.61) | $ | (0.73) |
Non-GAAP earnings (loss) per share — basic and diluted | $ | 0.20 | $ | (0.17) |
| | | | |
Weighted Average Number of Ordinary Shares Outstanding: | | | | |
Basic and diluted — GAAP | | 154,802 | | 153,050 |
Basic — Non-GAAP | | 154,802 | | 153,050 |
Diluted — Non-GAAP | | 160,472 | | 153,050 |
| | | | |
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income (loss) is as follows: | | | | |
Net Loss — GAAP | $ | (95,154) | $ | (111,880) |
Adjustments: | | | | |
Share-based compensation expense | | 50,975 | | 43,849 |
Amortization expense | | 32,316 | | 30,774 |
Depreciation expense | | 19,174 | | 17,495 |
Change in the fair value of warrants and equity method investments | | 967 | | 3,063 |
Non-cash net interest expense | | 361 | | 386 |
Change in the fair value of contingent consideration | | 21,500 | | (2,300) |
Income tax effect related to reconciling items | | (4,666) | | (8,052) |
Restructuring expense | | 3,598 | | — |
Debt refinacing charge | | 2,298 | | — |
Non-GAAP Net Income (Loss) | $ | 31,369 | $ | (26,665) |
| | | | |
| | | | |
Alkermes plc and Subsidiaries |
Selected Financial Information (Unaudited) |
| | | | |
Condensed Consolidated Balance Sheets | | June 30, | | December 31, |
(In thousands) | | 2018 | | 2017 |
Cash, cash equivalents and total investments | $ | 560,519 | $ | 590,716 |
Receivables | | 255,230 | | 233,590 |
Contract assets | | 14,582 | | — |
Inventory | | 87,165 | | 93,275 |
Prepaid expenses and other current assets | | 49,639 | | 48,475 |
Property, plant and equipment, net | | 296,635 | | 284,736 |
Intangible assets, net and goodwill | | 316,725 | | 349,041 |
Other assets | | 170,991 | | 197,394 |
Total Assets | $ | 1,751,486 | $ | 1,797,227 |
Long-term debt — current portion | $ | 2,843 | $ | 3,000 |
Other current liabilities | | 284,630 | | 288,122 |
Long-term debt | | 277,548 | | 278,436 |
Contract liabilities — long-term | | 5,857 | | 5,657 |
Other long-term liabilities | | 22,453 | | 19,204 |
Total shareholders' equity | | 1,158,155 | | 1,202,808 |
Total Liabilities and Shareholders' Equity | $ | 1,751,486 | $ | 1,797,227 |
| | | | |
Ordinary shares outstanding (in thousands) | | 155,303 | | 154,009 |
| | | | |
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the three months ended June 30, 2018, which the company intends to file in July 2018. |
